Sentence examples for vector toxicity from inspiring English sources

However, vector toxicity and transgene silencing have created significant barriers to vector applications to the brain.

Inefficient cytosolic delivery and vector toxicity contribute to the limited use of antisense oligonucleotides (ASOs) and siRNA as therapeutics.

Although gene therapy-mediated transdetermination of hepatic oval cells to authentic-looking and functioning β cells has been shown to reverse diabetes in mice, vector toxicity has precluded application of the technology in clinical trials.

Recent advances in vector design and production have built on increasing understanding of the basic biology of HSV to minimise vector toxicity and exploit viral features that give rise to lifelong latent infection in the nervous system.

Increased knowledge of virus structure and host cell interactions has led to reengineering of first-generation Ad vectors to improve tissue targeting, and this may improve transgene expression as well as reduce vector toxicity.

Other therapeutic strategies, such as gene therapy, have been explored but several limitations exist, which include low viral vector transduction efficiency, host immune response to the vector, and vector toxicity.

However issues such as vector immunogenicity, toxicity and restricted transduction to receptor-expressing cells have prevented broad clinical translation of these constructs.

Vector related toxicity could probably be avoided by applying a significantly lower viral dose since transgene expression within these new promoter systems was shown to be more than 4000-fold higher as compared with the CMV-promoter commonly used in clinical trials.

Second, they do not transfer any viral gene, thus alleviating the risk of vector-mediated toxicity and immune response against the transduced cells.

In order to evaluate Ad vector-mediated toxicity in neonatal mice following systemic administration, the levels of two liver toxicity markers, serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were examined following Ad vector administration.

Given that the only vector-related toxicity that has been observed to date in human trials of AAV gene therapy for hemophilia B is a dose-related immune response to the AAV capsid, our results support our strategy of generating rAAV8 stocks with minimal empty AAV particles as desirable to avoid immune activation.